25Aug
Johnson & Johnson Announces Acquisition of Momenta For $6.5 Billion
Johnson and Johnson announced that it has entered into an agreement to acquire Momenta Pharmaceuticals, Inc. for $6.5 billion. The acquisition gives J&J’s Janssen unit full global rights to Momenta’s nipocalimab (M281), an anti-FcRn antibody designed to treat a number of autoantibody-driven disorders, including generalized myasthenia gravis (gMG), warm autoimmune hemolytic anemia (wAIHA), and hemolytic disease of the fetus and newborn (HDFN)....
By:
Goodwin
Related
The annual gathering of life sciences executives and investors in San Francisco that many now call “...
Read More >
Franczek recently hosted an at capacity seminar on preventing workplace violence. As a follow-up to ...
Read More >
Apple announced that the coronavirus outbreak that’s brought Chinese manufacturing to a near-stands...
Read More >
Last week, the Internal Revenue Service (IRS) issued additional guidance on two outstanding issues r...
Read More >
HSR Act-driven Second Request responses require an uncommon balance of understanding, expertise, and...
Read More >
On October 28, 2019, the Ninth Circuit, following in the footsteps of the D.C. Circuit and the Secon...
Read More >